Safety & Efficacy of NBO in Acute Intracerebral Hemorrhage

Status Not yet recruiting

Clinical Trial Summary

Intracerebral hemorrhage (ICH) is one of the most devastating nontraumatic cerebral vascular diseases. Its exacerbation is often related to a mass effect because of hematoma formation and edema in the perihematoma, which plays a key role in disease deterioration. Perihematoma edema is an important contributor to brain injuries secondary to ICH and one of the risk factors that leads to disease deterioration and high mortality. Brain edema following ICH was believed to be induced by the breakdown of the blood-brain barrier and ischemia and hypoxia of the perihematoma.

Normobaric oxygen (NBO) therapy is a treatment that delivers high-flow oxygen at normobaric pressure through a facemask to supplement the oxygen supply,which maintain the oxygen concentration of typically 40-100% ,can increase the arterial oxygen content, and alleviate tissue hypoxia. NBO therapy has been shown to provide neuroprotection against ischemic stroke in an experimental study and a clinical trial. To the best of our knowledge, the potential of NBO therapy for neuroprotection against human hemorrhagic stroke has not been investigated.

There are two studies about NBO interventions in the rat model of intracerebral hemorrhage.The one showed NBO did not worsen hemorrhage severity or brain edema. There were no significant differences in hemorrhagic blood volumes or brain water content. NBO did not affect any of the neurological outcome tests in the primary or secondary studies. Another one showed NBO groups improved NSSs,decreased contents of brain water, HIF-1α and VEGF, and fewer apoptotic cells in the perihematoma at 72 h after ICH compared with the ICH control group. These results suggest that NBO therapy with oxygen delivered at 90% conferred best neuroprotection to ICH rats, potentially through amelioration of brain edema by suppressing HIF-1α and VEGF expression in the perihematoma.

But there is no clinical study on the safety and efficacy of NBO in patients with intracerebral hemorrhage.NBO has the advantages of simple operation, non-invasiveness and early application, which makes it have great application prospects in the treatment of ICH.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04144868
Study type	Interventional
Source	Capital Medical University
Contact
Status	Not yet recruiting
Phase	N/A
Start date	October 30, 2019
Completion date	December 30, 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04741334` - Mild Head Injury, Antiplatelets, and Anticoagulants
Completed	`NCT02565693` - Apixaban After Anticoagulation-associated Intracerebral Haemorrhage in Patients With Atrial Fibrillation	Phase 2
Recruiting	`NCT01866384` - Targeted Temperature Management After Intracerebral Hemorrhage	Phase 2
Completed	`NCT00029315` - Intraventricular Rt-PA in Patients With Intraventricular Hemorrhage	Phase 2
Active, not recruiting	`NCT06230419` - Retrospective Study on the Direction of Artificial Intelligence in Identifying Cranial Trauma CT Imaging
Recruiting	`NCT05118997` - Active Removal of IntraCerebral Hematoma Via Active Irrigation	N/A
Active, not recruiting	`NCT02258919` - Decompressive Hemicraniectomy in Intracerebral Hemorrhage	N/A
Completed	`NCT01472224` - Volume Measurement and Progression Surveillance of Intracerebral Haemorrhage Using Transcranial Ultrasound	N/A
Recruiting	`NCT06078020` - PLatform Study for INTracerebral Haemorrhage (PLINTH): Community-based Feasibility Study
Completed	`NCT01467206` - Life After STroke - the LAST Study	N/A
Completed	`NCT00226096` - Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage	N/A
Recruiting	`NCT03815149` - Safety and Clinical Effectiveness of Pipeline™ Shield Devices for Intracranial Aneurysms
Completed	`NCT00579943` - Regulation of Cerebral Blood Flow in Very Low Birth Weight Infants	N/A
Recruiting	`NCT05424614` - Study on the Prognostic Prediction Model of Patients With Acute Intracerebral Hemorrhage by Artificial Intelligence
Completed	`NCT03000283` - Conivaptan for the Reduction of Cerebral Edema in Intracerebral Hemorrhage- A Safety and Tolerability Study	Phase 1
Active, not recruiting	`NCT02283879` - Human Umbilical Cord Mesenchymal Stem Cell in Cerebral Hemorrhage Sequela	Phase 1
Active, not recruiting	`NCT02240394` - TCD Detection of Ophthalmic Artery Blood Flow Velocity Prediction Feasibility Study of Intracranial Pressure	N/A
Completed	`NCT01858675` - Biomarkers Correlation With Volemia	N/A
Completed	`NCT00363662` - Diagnostic Utility of MRI in Intracerebral Hemorrhage
Completed	`NCT03160677` - Blood Pressure Target in Acute Stroke to Reduce hemorrhaGe After Endovascular Therapy	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Safety and Efficacy of NBO in Acute Intracerebral Hemorrhage

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms